Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 1

Submit an article Journal homepage

981

Views

CrossRef citations to date

Altmetric

Reviews

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials

Rizwana ParveenCentre for Translational and Clinical Research, Jamia Hamdard, New Delhi110062, India

Nidhi Bharal AgarwalCentre for Translational and Clinical Research, Jamia Hamdard, New Delhi110062, IndiaCorrespondence[email protected]

Neelam KaushalMedical Affairs and Clinical Research, Sun Pharma Industries Ltd., Gurgaon122001, India

Ghanshyam MaliMedical Affairs and Clinical Research, Sun Pharma Industries Ltd., Gurgaon122001, India

Sheikh RaisuddinCentre for Translational and Clinical Research, Jamia Hamdard, New Delhi110062, India

Pages 105-115 | Published online: 09 Dec 2015

Cite this article
https://doi.org/10.1517/14656566.2016.1109629
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Google Scholar
Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267–1282.
PubMed Web of Science ®Google Scholar
Nadeau DA. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach. Postgrad Med. 2013;125(3):112–126.
PubMed Web of Science ®Google Scholar
Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med. 2011;124(Suppl 1):S19–S34.
PubMed Web of Science ®Google Scholar
Hinnen D. The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus. J Cardiovasc Nurs. 2013;28(2):157–165.
PubMed Web of Science ®Google Scholar
Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–950.
PubMed Web of Science ®Google Scholar
Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467–477.
PubMed Web of Science ®Google Scholar
Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
PubMed Web of Science ®Google Scholar
Kaushal S, Singh H, Thangaraju P, et al. Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am J Med Sci. 2014;6(3):107–113.
PubMedGoogle Scholar
Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–393.
PubMed Web of Science ®Google Scholar
Summary of product characteristics of INVOKANA. UK: Janssen-Cilag Ltd. [revised 2014 Nov 15; cited 2015 Jan 23]. Available from: http://ec.europa.eu/health/documents/community-register/2013/20131115127004/anx_127004_en.pdf
Google Scholar
Prescribing information of INVOKANA®. Silver Spring (MD): Janssen Pharmaceuticals Inc. [ revised 2014 Feb 19; cited 2014 Mar 30]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo.
Google Scholar
Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud. 2011;8:348–354.
PubMedGoogle Scholar
Kanwal A, Banerjee SK. SGLT inhibitors: a novel target for diabetes. Pharm Pat Anal. 2013;2(1):77–91.
PubMedGoogle Scholar
Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265–275.
PubMed Web of Science ®Google Scholar
Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453–467.
PubMedGoogle Scholar
Dietrich E, Powell J, Taylor JR. Canagliflozin: a novel treatment option for type 2 diabetes. Drug Des Devel Ther. 2013;7:1399–1408.
PubMed Web of Science ®Google Scholar
Colleen M, George LB. Blood pressure reduction: an added benefit of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429–430.
PubMed Web of Science ®Google Scholar
Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007.
PubMed Web of Science ®Google Scholar
Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
PubMed Web of Science ®Google Scholar
Panic N, Leoncini E, Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE. 2013;8(12):e83138.
PubMed Web of Science ®Google Scholar
Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. Endocr Disord. 2013;13:58.
PubMed Web of Science ®Google Scholar
Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
PubMed Web of Science ®Google Scholar

••This study evaluates the efficacy and safety of canagliflozin in combination with metformin and provides the evidence for the use of canagliflozin as an adjunct therapy

A randomized, double-blind, placebo-controlled, double-dummy, parallel group, multileft, dose-ranging study in subjects with type 2 diabetes mellitus to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with sitagliptin as a reference arm [cited 2014 Mar 15]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT00642278?term=NCT00642278&rank=1.
Google Scholar
Schernthaner G, Jorge LG, Julio R, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508–2515.
PubMed Web of Science ®Google Scholar
An efficacy, safety, and tolerability study of canagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin alone or in combination with a sulphonylurea [cited 2014 Mar 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01381900?term=01381900&rank=1.
Google Scholar
Bode B, Stenlöf K, Sullivan D, et al. A safety and efficacy study of canagliflozin in older patients (55 to 80 years of age) with type 2 diabetes mellitus. Hosp Pract (1995). 2013;41(2):72–84.
PubMedGoogle Scholar
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;5:463–473.
Web of Science ®Google Scholar

•This study provides evidence that canagliflozin may be suitable for use in diabetics with chronic kidney disease as a comorbidity

Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545.
PubMed Web of Science ®Google Scholar
Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
PubMed Web of Science ®Google Scholar
An efficacy, safety, and tolerability study of canagliflozin in patients with type 2. Diabetes mellitus who have moderate renal impairment [cited 2014 Mar 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01064414?term=nct01064414&rank=1.
Google Scholar
Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163–175.
PubMed Web of Science ®Google Scholar

•This study evaluates the long-term effect of canagliflozin administered as a monotherapy in large number of diabetes mellitus type 2 patients

Nobuya I, Kazuoki K, Toru Y, et al. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Invest. 2015;6:210–218.
PubMed Web of Science ®Google Scholar
Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS ONE. 2015;10(4):e0125879.
PubMed Web of Science ®Google Scholar
Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes. 2014;5(6):854–859.
PubMedGoogle Scholar
Hao WL, Chin HT. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:6. Article ID 719578.
Google Scholar
Mujahid AS, Parth N. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther. 2014;8:2493–2505.
PubMed Web of Science ®Google Scholar
Sanjay K, Rakesh S, Yashdeep G. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015;19(4):524–528.
PubMedGoogle Scholar
Juan FM, Lillian S, Emily E, et al. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes. A drug class overview. P T. 2015;40(7):451–462.
PubMedGoogle Scholar
Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693.
PubMed Web of Science ®Google Scholar
Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–1686.
PubMed Web of Science ®Google Scholar
Summary of product characteristics of INVOKANA. UK: Janssen-Cilag Ltd. [ revised 2015 Aug 20; cited 2015 Aug 30]. Available from: https://www.medicines.org.uk/emc/medicine/28401.
Google Scholar
Silvio E, Richard MB, John BB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-lefted approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
PubMed Web of Science ®Google Scholar
Dennis JC, Terri LL, Danial EB. Formulary drug reviews: dapagliflozin. Hosp Pharm. 2014;49(7):647–662.
PubMedGoogle Scholar
Yehuda H, Zachary TB, George G, et al. American association of clinical endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
Google Scholar
Nigro SC, Riche DM, Pheng M, et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother. 2013;47(10):1301–1311.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials

Bibliography

••This study evaluates the efficacy and safety of canagliflozin in combination with metformin and provides the evidence for the use of canagliflozin as an adjunct therapy

•This study provides evidence that canagliflozin may be suitable for use in diabetics with chronic kidney disease as a comorbidity

•This study evaluates the long-term effect of canagliflozin administered as a monotherapy in large number of diabetes mellitus type 2 patients

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials

Bibliography

••This study evaluates the efficacy and safety of canagliflozin in combination with metformin and provides the evidence for the use of canagliflozin as an adjunct therapy

•This study provides evidence that canagliflozin may be suitable for use in diabetics with chronic kidney disease as a comorbidity

•This study evaluates the long-term effect of canagliflozin administered as a monotherapy in large number of diabetes mellitus type 2 patients

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date